1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

REMS For Mavacamten Could Involve Additional Monitoring, BMS Says

User Fee Delayed; Potential For Systolic Dysfunction Needs Watching

 
• By Mandy Jackson

The FDA will take three more months to review mavacamten, a treatment for hypertrophic cardiomyopathy that BMS expects to be one of the company’s next blockbusters. 

Stethoscope And Stress Ball In Heart Shape On Wooden Background
The action date for mavacamten has moved from 28 January to 28 April • Source: Alamy

A delay in the user fee deadline for Bristol Myers Squibb Company’s cardiac drug mavacamten over a proposed risk evaluation and mitigation strategy (REMS) could involve the need for additional monitoring, the company told Scrip. It remains to be seen if the REMS requirements could diminish mavacamten’s profile versus a competitor with a similar mechanism of action.

The 90-day extension of the US Food and Drug Administration review deadline, announced 19 November, shifts the action date for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

More from Therapy Areas

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.